Brief: Senti Bio Announces Pipeline Prioritization, Updates Cash Runway Guidance

Senti Biosciences Holdings

27/01/2023 12:34

Jan 27 (Reuters) - Senti Biosciences Inc  SNTI.O :
    * SENTI BIO ANNOUNCES PIPELINE PRIORITIZATION TO FOCUS ON
LOGIC
GATED CELL THERAPIES; UPDATES CASH RUNWAY GUIDANCE
    * SENTI BIOSCIENCES INC - SENTI-202 ON TRACK FOR IND FILING
IN 2H
2023
    * SENTI BIOSCIENCES INC - CASH RUNWAY GUIDANCE EXTENDED
THROUGH AT
LEAST Q1 2024
    * SENTI BIOSCIENCES INC - CONTINUING ITS STRATEGIC RESEARCH
COLLABORATIONS WITH SPARK THERAPEUTICS ON NEXT-GENERATION AAV
GENE THERAPY
    * SENTI BIOSCIENCES INC - COMPANY DOES NOT INTEND TO INVEST
IN THE
CLINICAL DEVELOPMENT OF SENTI-301A, FOR THE TREATMENT OF
HEPATOCELLULAR CARCINOMA
    * SENTI BIOSCIENCES INC - CONTINUING ITS STRATEGIC RESEARCH
COLLABORATIONS WITH BLUEROCK THERAPEUTICS ON IPSC-DERIVED CELL
THERAPIES
    * SENTI BIOSCIENCES INC - COMPANY IS ACTIVELY PURSUING
STRATEGIC
GEOGRAPHIC PARTNERSHIPS FOR CLINICAL DEVELOPMENT OF SENTI 301A

Further company coverage:  SNTI.O 
 ((Reuters.Briefs@thomsonreuters.com;))